Industry stakeholders discussed the proposed EU Biotech Act as a lever to improve European biotech competitiveness, with emphasis on manufacturing supply chains and harmonized pathways to market. EuropaBio’s Claire Skentelbery said the proposal is a “generational opportunity,” while noting that execution may lag without simplified and harmonized rules. Speakers cited persistent barriers including multi-country clinical trial frameworks that sponsors have found cumbersome, as well as fragmented national requirements that can slow coordination. The discussion also pointed to venture capital and scaling dynamics pushing smaller European biotechs to the US or other regions. For biotech leaders planning trials and commercialization, the act’s negotiating trajectory will likely influence trial design strategies, partner selection, and where companies choose to build manufacturing and late-stage development.